(C) administering to said patient a first targetable conjugate which comprises a carrier portion and one or more conjugated enzymes, wherein said carrier portion comprises or bears at least one epitope recognizable by said at least one other arm of said bi-specific antibody or antibody fragment; and

(D) administering to said patient

(1) a prodrug, when said enzyme is capable of converting said prodrug to a drug at the target site; or

(2) a drug which is capable of being detoxified in said patient to form an intermediate of lower toxicity, when said enzyme is capable of reconverting said detoxified intermediate to a toxic form, and, therefore, of increasing the toxicity of said drug at the target site, or

(3) a prodrug which is activated in said patient through natural processes and is subject to detoxification by conversion to an intermediate of lower toxicity, when said enzyme is capable of reconverting said detoxified intermediate to a toxic form, and, therefore, of increasing the toxicity of said drug at the target site, or

D1 cont

(4) a second targetable conjugate which comprises a carrier portion which comprises or bears at least one epitope recognizable by said at least one other arm of said bi-specific antibody or antibody fragment, and a prodrug, when said enzyme is capable of converting said prodrug to a drug at the target site.

30. (Twice Amended) A kit useful for treating diseased tissues in a patient comprising:

D2

(A) a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable conjugate;

(B) a first targetable conjugate which comprises a carrier portion and one or more conjugated enzymes, wherein said carrier portion comprises or bears at least one

epitope recognizable by said at least one other arm of said bi-specific antibody or antibody fragment;

(C) optionally, a clearing composition useful for clearing non-localized antibodies and antibody fragments; and

(D) (1) a prodrug, when said enzyme is capable of converting said prodrug to a drug at the target site; or

(2) a drug which is capable of being detoxified in said patient to form an intermediate of lower toxicity, when said enzyme is capable of reconverting said detoxified intermediate to a toxic form, and, therefore, of increasing the toxicity of said drug at the target site, or

(3) a prodrug which is activated in said patient through natural processes and is subject to detoxification by conversion to an intermediate of lower toxicity, when said enzyme is capable of reconverting said detoxified intermediate to a toxic form, and, therefore, of increasing the toxicity of said drug at the target site, or

D3 cont'd

(4) a second targetable conjugate which comprises a carrier portion which comprises or bears at least one epitope recognizable by said at least one other arm of said bi-specific antibody or antibody fragment, and a prodrug, when said enzyme is capable of converting said prodrug to a drug at the target site.

51. (Amended) The method of claim 1, wherein (D) comprises administering a prodrug and said enzyme is capable of converting said prodrug to a drug at the target site.

D3

52. (Amended) The method of claim 1, wherein (D) comprises administering a prodrug that is activated in said patient through natural processes and is subject to detoxification by conversion to an intermediate of lower toxicity, and said enzyme is capable of reconverting the detoxified intermediate to a toxic form, and, therefore, of increasing the toxicity of said drug at the target site.

Please add the following new claims:

55. (New) The method of claim 1, further comprising, when said first targetable conjugate additionally comprises a prodrug, administering a second targetable conjugate which comprises a carrier portion which comprises or bears at least one epitope recognizable by said at least one other arm of said bi-specific antibody or antibody fragment, and an enzyme capable of converting said prodrug to a drug or of reconverting a detoxified intermediate of said drug to a toxic form.

56. (New) The kit of claim 30, further comprising, when said first targetable conjugate additionally comprises a prodrug, a second targetable conjugate which comprises a carrier portion which comprises or bears at least one epitope recognizable by said at least one other arm of said bi-specific antibody or antibody fragment, and an enzyme capable of converting said prodrug to a drug or of reconverting a detoxified intermediate of said drug to a toxic form.